Prostate Cancer Clinical Trial
MRI Before Biopsy in Diagnosing Patients With Prostate Cancer
Summary
This pilot clinical trial studies how well magnetic resonance imaging (MRI) before biopsy works in diagnosing patients with prostate cancer. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. This diagnostic procedure may aid in identifying lesions in the prostate which may have cancer. The lesions can then be targeted during the prostate biopsy to improve the accuracy of identifying prostate cancer.
Full Description
PRIMARY OBJECTIVES:
I. Identification of one of more lesions suspicious for prostate cancer using a novel MRI protocol, not identified by transrectal ultrasound (TRUS) alone and to determine if the lesions identified by MRI demonstrate clinically significant prostate cancer based on pathologic findings (ie. Gleason >= 7 or percentage of core involved with cancer > 50%).
SECONDARY OBJECTIVES:
I. Average time for MRI scan per patient. II. Correlation of lesions on MRI to radical prostatectomy specimens. III. To determine whether MRI 3 dimensional (3D) T2 half-Fourier acquired single turbo spin-echo (HASTE) or sampling perfection with application optimized contrast using different flip angle evolutions (SPACE) protocols provide improved rates of prostate cancer detection.
IV. Yield of additional clinically significant prostate cancer diagnoses based on MRI targeted lesions on biopsy.
V. Rate of benign pathology identified by MRI (i.e. false positives). VI. To compare costs associated with the use of MRI over TRUS biopsy alone.
OUTLINE:
Participants undergo pelvic MRI. Within 1-2 weeks, patients undergo scheduled prostate biopsy.
Eligibility Criteria
Inclusion Criteria:
Abnormal prostate-specific antigen (PSA) blood test
> 2.5 ng/mL for men < 50 years (yrs) of age
> 3.5 ng/mL for men < 60 yrs of age
> 4.5 ng/mL for men < 70 yrs of age
Abnormal digital rectal exam (i.e. palpable nodule, induration or firm area to the prostate)
Scheduled for a TRUS biopsy based on clinical suspicion for prostate cancer
Exclusion Criteria:
Individuals who have previously undergone biopsy of the prostate for diagnosis of prostate cancer
Contraindications to TRUS/prostate biopsy (BX)
Currently on blood thinning agents (Plavix, Coumadin etc.) or bleeding disorder
Active urinary tract infection
Acute painful perianal disorder (i.e. rectal abscess)
Contraindications to MRI
Patients with ferromagnetic or otherwise non-MRI compatible aneurysm clips
The presence of an implanted pacemaker or implanted defibrillator device
Patients with contraindications for MRI due to embedded foreign metallic objects: bullets, shrapnel, metalwork fragments, or other metallic material adds unnecessary risk to the patient
Implanted medical device not described above that is not MRI-compatible
Known history of claustrophobia
Individuals with a short life expectancy (< 10 years)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Cleveland Ohio, 44106, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.